Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Interventions
TAB004, Toripalimab
Drug
Lead sponsor
TopAlliance Biosciences
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Conditions
Advanced Solid Tumor
Interventions
DS-1471a
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sarasota, Florida • Milwaukee, Wisconsin
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy
Procedure · Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Asthma
Interventions
SM17, Placebo
Biological · Other
Lead sponsor
SinoMab BioScience Ltd
Industry
Eligibility
19 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Solid Tumor
Interventions
Hu5F9-G4
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Grand Rapids, Michigan + 3 more
Conditions
COVID-19
Interventions
mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
Conditions
CD123+ Acute Myeloid Leukemia
Interventions
ORM-1153
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Grand Rapids, Michigan • Houston, Texas
Conditions
Health Participants
Interventions
BMS-986209, BMS-986209 Placebo, Itraconazole, Diltiazem
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Conditions
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
Interventions
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
Drug · Diagnostic Test
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Intestinal Anastomosis Complication
Interventions
Magnamosis
Device
Lead sponsor
Michael Harrison
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California
Conditions
Non Hodgkin Lymphoma, Solid Tumor
Interventions
SB-4826, Rituximab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
La Jolla, California
Conditions
Hematologic Cancer
Interventions
ABBV-101
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Conditions
Hematological Malignancy, Lymphoma
Interventions
SG2501
Drug
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
8
States / cities
Atlanta, Georgia • Hackensack, New Jersey • Hawthorne, New York + 5 more
Conditions
Healthy Volunteers
Interventions
RG-HRV16, Placebo
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Solid Tumor, Non-Small Cell Lung Carcinoma, Esophageal Adenocarcinoma, SMARCA4 Mutation, Gastroesophageal Junction Squamous Cell Carcinoma, Advanced Solid Tumor
Interventions
PLX-61639
Drug
Lead sponsor
Plexium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 7 more
Conditions
Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Interventions
BMS-936564 (Anti-CXCR4)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 7 more
Conditions
Advanced Solid Tumor
Interventions
YL217, Bevacizumab, 5-FU with leucovorin
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • New Haven, Connecticut + 9 more
Conditions
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Interventions
AZD8701, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 101 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Combination Product · Drug
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
Conditions
Thrombin Inhibition
Interventions
AZD8165
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Neoplasms, Myelogenous Leukemia, Acute
Interventions
RO6839921
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • St Louis, Missouri • Charleston, South Carolina
Conditions
Advanced Solid Tumors
Interventions
DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
8
States / cities
San Diego, California • Jacksonville, Florida • Louisville, Kentucky + 5 more